The ACTR2 antibody targets Actin-Related Protein 2 (ACTR2), a key component of the ARP2/3 complex, which plays a critical role in regulating actin cytoskeleton dynamics. The ARP2/3 complex facilitates actin nucleation, branching, and reorganization, processes essential for cell motility, membrane trafficking, and cytokinesis. ACTR2. along with ARP3. forms the structural core of this complex, enabling it to bind existing actin filaments and nucleate new branches, thereby driving cellular shape changes and movement. Dysregulation of ACTR2 or the ARP2/3 complex is implicated in pathological conditions, including cancer metastasis, immune cell dysfunction, and neurological disorders.
ACTR2 antibodies are widely used in research to study actin polymerization mechanisms, cell migration, and intracellular transport. They are employed in techniques such as Western blotting, immunofluorescence, and immunoprecipitation to visualize ACTR2 expression, localization, and interactions. Commercially available ACTR2 antibodies are typically raised in rabbits or mice, with validation across species like humans, mice, and rats. These tools have advanced understanding of how cytoskeletal remodeling contributes to developmental processes, infection pathways (e.g., pathogen invasion), and metastatic behaviors in tumors. Ongoing research continues to explore ACTR2 as a potential therapeutic target for diseases linked to cytoskeletal abnormalities.